Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.

Clinical pharmacology and therapeutics - 1 Sept 2013

Sorich M J, Polasek T M, Wiese M D

Abstract excerpt

From 2010 to 2012, nine systematic reviews reported highly variable conclusions regarding the association between carriage of a cytochrome P450 2C19 loss-of-function allele and the risk of adverse cardiovascular (CV) events in individuals using clopidogrel. Possible contributors to the variable findings include differences in patient populations, CV end points, and statistical models utilized by the systematic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clopidogrel
Share to Endpoint Determination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Meta-Analysis as Topic

Share to Patient Selection

Share to Platelet Aggregation Inhibitors

Share to Publication Bias

Share to Review Literature as Topic

Share to Ticlopidine

Source

Identifiers

PMID: 23670120
DOI: 10.1038/clpt.2013.100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.PMID 23670120Read ↗

A systematic review and critical assessment of 11 discordant meta-analyses on reduced-function CYP2C19 genotype and risk of adverse clinical outcomes in clopidogrel users.Semantic proximity Read ↗

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Semantic proximity Read ↗

CYP2C19 and effect of clopidogrel for secondary prevention of major ischemic events: systematic review and meta-analysisSemantic proximity Read ↗

CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.Semantic proximity Read ↗

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.Semantic proximity Read ↗

Clopidogrel PharmacogeneticsSemantic proximity Read ↗

Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.Semantic proximity Read ↗

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Semantic proximity Read ↗

Clopidogrel: a case for indication-specific pharmacogenetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.